A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2)

✍ Scribed by J.-P. Glossmann; A. Josting; B. Pfistner; U. Paulus; A. Engert; German Hodgkin's Lymphoma Study Group (GHSG)

• Publisher: Springer
• Year: 2002
• Tongue: English
• Weight: 90 KB
• Volume: 81
• Category: Article
• ISSN: 0939-5555
• DOI: 10.1007/s00277-002-0495-y